How to Bill Using CPT Code 96132 for Neuropsychological Testing
Disclaimer Please note that Creyos Health can not determine...
Read more
Creyos offers pre-made, scientifically-validated, protocols to test for conditions like attention deficit hyperactivity disorder (ADHD) and mild cognitive impairment (MCI). Proprietary and condition-specific, these cognitive testing batteries help providers quickly and accurately detect, test, treat, and track conditions causing cognitive impairment.
Developed by neuroscientists, protocols are supported by 30 years of research and a robust normative database, making them it a scientifically superior options for objective condition testing.
Premade cognitive batteries target specific conditions, providing testing with greater sensitivity for dementia than MoCA or MMSE and the ability to detect objective markers for conditions like ADHD.
Condition-focused protocols generate concise reports displaying patient performance on cognitive assessments, enabling quick identification of cognitive issues.
Condition-focused protocols have been carefully designed based on extensive scientific review and validation. The cognitive tests and questionnaires that comprise each protocol are all proven to align with markers and brain function of the conditions being tested. They leverage hundreds of proprietary and condition-specific research studies to ensure maximum specificity and sensitivity.
Condition-focused protocols are designed for effortless administration by healthcare professionals and ease of completion for patients. Pre-selected tasks and questionnaires streamline setup, while embedded instructions ensure a seamless patient experience, setting expectations for each step and clearly guiding them through the requirements.
Creyos offers providers an end-to-end solution for cognitive screening, assessment, and care, helping to save practices time while delivering a better patient experience.
Creyos enables quick screening for measuring cognitive impairment in a patient-friendly two-task assessment. The test takes under 5-minutes to complete and is as easy to administer as the Montreal cognitive assessment (MoCA test) but sensitive enough to detect even mild cognitive impairment (MCI). With a clear report, it informs healthcare providers the degree of cognitive impairment and whether further cognitive testing is required.
If further testing is needed after the initial cognitive screen, Creyos offers a comprehensive 20-minute diagnostic assessment. This includes four additional tasks and behavioral health questionnaires to precisely measure cognitive function, resembling traditional neuropsychological testing. The test evaluates short-term memory, reasoning, and verbal ability, and provides easy-to-interpret reports for healthcare providers, highlighting indicators of dementia or Alzheimer's disease.
If there are signs of developing dementia or Alzheimer's disease, Creyos enables providers to create cognitive care plans that address medication, lifestyle changes, risk factors and support services for caregivers or family members. Unlike other cognitive assessment tools, care plans in Creyos align to Alzheimer's Association guidelines. They enable coordinated care and keep patients, primary care providers, specialists, and caregivers in sync for better patient outcomes.
The Creyos cognitive assessment for mild cognitive impairment enables easy re-testing. Providers can measure progression of cognitive impairment over time to objectively determine the effectiveness of cognitive care plans. They can address cognitive complaints with data-driven, longitudinal reports, helping to ease patient and family member anxiety about symptom progression.
We've seen that patients are more invested in their health and they pay more attention to the deficits that showed up in testing. During follow up appointments, they let us know if things have gotten better or worse. We can re-test them using quantitative measures and show them the side-by-side comparison to their earlier results
The Creyos ADHD protocol includes a battery of cognitive tests to measure attention and executive function, including a sustained attention to response task (the SART) that measures continuous performance. Performance on these tasks is measured against the typical range for 14 specific ADHD markers, to show whether a patient falls in or out of norms.
The protocol includes an optional, age-appropriate questionnaire that can include the ASRS or SWAN depending on whether cognitive testing is for a pediatric or adult patient. Providers also have the option of administering the VADRS to assess for ADHD and comorbidities.
After ADHD cognitive testing, providers receive a detailed report indicating whether patients fall within the typical range for ADHD markers. The report includes a details section for additional context on each task and its markers, enabling providers to assess proximity to the threshold. Behavioral problems and ADHD symptoms tied to questionnaire responses are also highlighted for quick identification and easier communication with patients.
Creyos supports my decision-making. Having these reports gives me clear answers about where there are deficits, like in attention, versus other types of measures. I’m really able to read out a patient’s specific symptoms and target which medication I think will work best for them
Disclaimer Please note that Creyos Health can not determine...
Read more
With greater public awareness of attention deficit...
Read more
Can a brain scan show the differences between the brain of...
Read more